Kompânijai jâsamazina ARV preparâtu cenas
Apskatît komentârus (0)
20.04.2013
Tikðanâs laikâ tika prezentçti kompânijas veiktie jauno preparâtu pçtîjumi, informâcija par ARV preparâtu reìistrâcijas statusu reìiona valstîs, ViiV politika brîvprâtîgo licenèu izsniegðanâ, kâ arî ierosinâts jautâjums par piekïuvi konkrçtiem ARV preparâtiem un to cenu.
Tâpat tikðanâs laikâ tika pausta EECA CAB pozîcija, tajâ skaitâ aktîvistu viedoklis, ka kompânijai ViiV ir jâsamazina reìionâ plaði izmantotu preparâtu („Combivir”, „Kivexa”, „Ziagen” u.c.) cenas, kâ arî jârîkojas, lai ðos preparâtus reìistrçtu valstîs, kur tie nav reìistrçti un tâpçc tos drîkst izmantot tikai donoru programmu ietvaros. Tâdçjâdi tiks novçrsts risks, ka pçc donoru aizieðanas var bût pârtraukta HIV infekcijas ârstçðana.
Ar pacientu apvienîbas Konsultatîvâs padomes pozîciju daudz detalizçtâk var iepazîties tikðanâs protokolâ ar farmâcijas kompâniju ViiV Healthcare:
http://itpcru.org/netcat_files/File/EECA_CAB_meeting_ViiV_Healthcare_07_02_2013_RUS_F.pdf
vai
http://ecuo.org/media/filer_public/2013/04/03/eeca_cab_meeting_viiv_rus_f.pdf
**********************************************************
EECA CAB finds that ViiV should review its pricing policy in the region in the direction of a significant price reduction in order to improve access to treatment, especially with respect to the widely used drugs in the EECA region (including "Combivir", "Kivexa" and “Ziagen”). At the moment, the prices are oriented towards the formal classification of countries by income and they do not reflect the specifics of the epidemic and the situation with public health service in the region.
Read full minutes at http://itpcru.org/netcat_files/File/EECA_CAB_meeting_ViiV_Healthcare_07_02_2013_ENG_F.pdf
Atpakaï